At a glance
- Originator Takeda
- Class Cytostatic antibiotics
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Oct 2000 Discontinued-Preclinical for Cancer in Japan (Unknown route)
- 12 Jun 2000 Profile reviewed but no significant changes made
- 17 Jul 1998 Profile reviewed